RXRX Stock Holds Steady As Insider Form 4 Filings Stack Up

Recursion Pharmaceuticals Inc. stocks have been trading up by 8.78 percent following bullish sentiment around its latest AI drug-discovery advancements.

Live Update At 12:34:58 EDT: On Thursday, September 17, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 8.78%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX is trading like a classic early‑stage biotech: heavy on promise, light on profits, and currently stuck in a tight range. Over the past several weeks, Recursion Pharmaceuticals has mostly chopped between about $3.20 and $3.60, with recent daily closes clustering near $3.40–$3.50. That tells traders supply and demand are roughly balanced for now.

Intraday, RXRX showed a controlled grind higher, moving from about $3.24 in premarket toward $3.47 into midday, with only shallow pullbacks. That’s constructive price action for short‑term traders who like clean trends and tight risk.

Fundamentals, however, are brutal in the near term. RXRX booked roughly $74.3M in revenue over the trailing period, but the latest quarterly report shows about $7.3M in revenue against $142.3M in total expenses. Net loss came in near $131M, or about -$0.25 per share, plus EBITDA at roughly -$112.5M. Margins are deeply negative, with profit metrics showing large red numbers across the board.

On the balance sheet, though, RXRX has real runway. The company sits on about $545.7M in cash and equivalents, a current ratio near 5, and very low debt relative to equity. For traders, that combination — big losses but strong liquidity — sets RXRX up as a speculative story where sentiment and catalysts, not current earnings, drive the trading.

Why Traders Are Watching RXRX Insider Filings

RXRX has now seen a string of Form 4 filings in 2026/09, all tied to changes in beneficial ownership by insiders. On 2026/09/16, a Form 4 disclosed another insider change. Earlier, on 2026/09/02 and 2026/09/10, additional Form 4s reported similar shifts in RXRX insider holdings.

What matters for traders is not just that these filings exist, but what they actually tell you — and in this case, they don’t say much. None of the reports specify whether the insider transactions were purchases, sales, or equity awards. They also don’t lay out who traded or the size of the moves. That lack of detail makes it hard to treat any single Form 4 as a strong bullish or bearish signal for RXRX.

In many small‑cap names, a clear insider buying spree can light a fire under the stock. The reverse is true when insiders dump size into strength. Here, RXRX traders are getting only partial information. So far, price action agrees: the stock has stayed mostly range‑bound around the mid‑$3s even as these filings hit.

For active traders, that means RXRX remains a “news‑plus‑chart” play rather than an insider‑driven story. The filings are useful as background — they confirm insiders are active in some way — but they do not give a clean edge. Instead, traders are likely to lean harder on intraday levels, liquidity, and broader sentiment in biotech and AI‑driven drug discovery when planning trades in RXRX.

Conclusion

RXRX sits at an interesting crossroads for traders. On one side, Recursion Pharmaceuticals is burning cash fast, with about -$105.9M in operating cash flow in the latest quarter and free cash flow near -$107.9M. Profitability metrics are deeply negative, and traditional valuation tools like P/E don’t really apply. On the other side, RXRX holds more than half a billion dollars in cash, low debt, and a price‑to‑book ratio under 2, which helps support the current trading range.

Layer the insider picture on top of that, and the message is still cloudy. Three separate Form 4 filings in September show changes in beneficial ownership of RXRX, but with no clarity on whether insiders bought, sold, or simply received equity. For short‑term traders, that’s noise, not a catalyst. The real edge in RXRX, at least right now, comes from reading the tape — watching how the stock behaves around key levels like $3.20 support and the $3.60–$3.70 resistance zone.

Traders in the Tim Sykes community know the drill here: treat RXRX as a speculative trading vehicle, not a long‑term safety play. As Tim often says, “The market doesn’t care about your opinion, only about price and volume.” That mindset pairs directly with another one of his core trading principles: As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.”. For RXRX, those two inputs — plus disciplined risk management — matter far more than these vague insider filings. This analysis is for educational and research purposes only, and every trader needs to do their own homework before taking any trade in RXRX.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks